3,883
edits
Changes
no edit summary
Table 1. A comprehensive list of copy number alterations detectable by CMA testing with strong diagnostic, prognostic and treatment implications in AML. Clinical significance and level of evidence are defined as described in the methods.
{| class="wikitable"
{| class="wikitable"
|-
|-
|-
|-
|}
|}
D- diagnostic significance; P-prognostic significance; T- therapeutic significance. Classification of levels of evidence: Level 1- WHO classification or professional practice guidelines; Level 2- well-powered studies with consensus from experts in the field; Level 3- multiple small studies without any contradicting data; Level 4- individual small studies, case reports, preclinical studies.
CMA indicates chromosomal microarray; CNA indicates copy number aberration; CN-LOH indicates copy-neutral loss-of-heterozygosity; AML indicates acute myeloid leukemia; NK-AML indicates normal karyotype AML; pAML indicates primary AML; and sAML indicates secondary AML.
* indicates CNAs and CN-LOH regions that are predominantly seen in AML.
==References==
==References==